Accelerate Investment Advisors LLC Purchases 224 Shares of Johnson & Johnson (NYSE:JNJ)

Accelerate Investment Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.6% in the first quarter, HoldingsChannel reports. The firm owned 2,007 shares of the company’s stock after buying an additional 224 shares during the quarter. Accelerate Investment Advisors LLC’s holdings in Johnson & Johnson were worth $333,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Tallon Kerry Patrick purchased a new stake in Johnson & Johnson in the fourth quarter worth about $290,000. Capital & Planning LLC grew its stake in shares of Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock valued at $221,000 after acquiring an additional 183 shares during the period. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $85,886,000. Finally, BXM Wealth LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $799,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on JNJ. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Morgan Stanley increased their price target on Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Bank of America lowered their price objective on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Wall Street Zen cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Trading Down 1.1%

JNJ stock opened at $150.77 on Thursday. The firm has a fifty day moving average price of $154.06 and a 200 day moving average price of $153.67. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a market cap of $362.76 billion, a PE ratio of 16.77, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.45%. Johnson & Johnson’s dividend payout ratio is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.